Febuxostat may decrease the incidence of COVID-19 infection among patients with gout: a retrospective cohort study
In this retrospective cohort study, Febuxostat use was associated with a lower risk of COVID-19 among patients with gout for 3 years follow-up, even with renal impairment or tophus.
Authors
- Shiow‐Ing Wang (ORCID: https://orcid.org/0000-0003-3407-9020)
- Yongsheng Fan (ORCID: https://orcid.org/0000-0002-7466-8156)
- Weijie Wang (ORCID: https://orcid.org/0000-0002-5717-3602)
- Yang Cheng (ORCID: https://orcid.org/0000-0001-5356-043X)
- James Cheng-Chung Wei
- Xinchang Wang (ORCID: https://orcid.org/0000-0003-4763-2120)
Institutions
- Zhejiang Chinese Medical University (CN)
- China Medical University (TW)
- Chung Shan Medical University Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fphar.2025.1654173
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang Chinese Medical University
- Chung Shan Medical University
- Chung Shan Medical University Hospital